Company Filing History:
4 out of 96 
1 out of 832,843 Years Active: 2014-2020
Title: **Stefan Gross: Innovator in Cell Proliferation Disorders**
Introduction
Stefan Gross, an accomplished inventor based in Brookline, MA, has made significant contributions to the field of biomedical research, particularly in the diagnosis and treatment of cell proliferation disorders. With a portfolio boasting five patents, his work continues to impact healthcare by addressing critical challenges associated with mutant IDH enzymes.
Latest Patents
Among his latest innovations are two noteworthy patents:
1. **Methods for Diagnosing IDH-Mutant Cell Proliferation Disorders** - This patent provides methods for diagnosing individuals who have or are suspected of having cell proliferation-related disorders linked to mutant IDH enzymes exhibiting 2HG neoactivity.
2. **Methods and Compositions for Cell-Proliferation-Related Disorders** - This patent outlines methods for treating and evaluating subjects with neoactive mutants, offering new avenues for therapeutic interventions in affected populations.
Career Highlights
Stefan Gross has worked with notable companies, including Agios Pharmaceuticals, Inc., where he contributed to innovative research aimed at addressing genetic mutations that drive cell proliferation disorders. His expertise and inventive mind have made him an integral part of his teams.
Collaborations
Throughout his career, Gross has collaborated with esteemed colleagues like Shengfang Jin and Shin-San Michael Su. These partnerships have further enhanced the research and application of methods that revolutionize patient diagnostics and treatment options.
Conclusion
Stefan Gross exemplifies the spirit of innovation in the medical field, particularly in addressing complex disorders through targeted research and patenting. His contributions continue to pave the way for advancements in understanding and treating cell proliferation disorders, marking him as a key figure in contemporary biomedical science.